Management of Immune Compromised Transplant and Immune Effector Cell Treated Patients in the Setting of the COVID-19 Viral Pandemic: The OHSU Experience

The year 2020 is unlike any other in our lifetime. The world is currently experiencing a viral pandemic with the COVID-19 virus that has infected millions of people with a mortality in the hundreds of thousands. Immune-suppressed patients are among the group of people at a higher risk of mortality due to this virus. Therefore, the practice of hematopoietic cell transplant and cellular therapy has had to evolve to best protect patients, caregivers, and hospital staff. These changes affect all aspects of the transplant process from patient selection, donor product acquisition, inpatient/outpatient management, and research efforts.